Vivet Therapeutics to Present Key Findings on its Gene Therapy Program for Cerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting
November 14, 2024 03:30 ET
|
Vivet Therapeutics
Vivet Therapeutics to Present Key Findings on its Gene Therapy Program for Cerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting Gene therapy...
Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024
October 22, 2024 03:30 ET
|
Vivet Therapeutics
Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024 Paris,...
Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
October 23, 2023 07:30 ET
|
Vivet Therapeutics
Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress Paris, France, October 23, 2023 (GLOBE NEWSWIRE) – Vivet Therapeutics...
VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
August 12, 2021 07:00 ET
|
Vivet Therapeutics
VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease Paris, France and New York, NY, August 12, 2021 – Vivet Therapeutics (“Vivet”), a clinical-stage...
Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting
May 10, 2021 10:00 ET
|
Vivet Therapeutics
Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting Compelling...
Vivet Therapeutics y Pfizer Inc reciben autorización de la FDA para iniciar GATEWAY, ensayo clínico de fase 1/2 con VTX-801, la terapia génica de Vivet para la enfermedad de Wilson
November 18, 2020 01:00 ET
|
Vivet Therapeutics
Vivet Therapeutics y Pfizer Inc reciben...
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease
November 18, 2020 01:00 ET
|
Vivet Therapeutics
Vivet Therapeutics and Pfizer...